1. Home
  2. TPCS vs KLRS Comparison

TPCS vs KLRS Comparison

Compare TPCS & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TPCS
  • KLRS
  • Stock Information
  • Founded
  • TPCS 1956
  • KLRS 2019
  • Country
  • TPCS United States
  • KLRS United States
  • Employees
  • TPCS N/A
  • KLRS N/A
  • Industry
  • TPCS Metal Fabrications
  • KLRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TPCS Industrials
  • KLRS Health Care
  • Exchange
  • TPCS Nasdaq
  • KLRS Nasdaq
  • Market Cap
  • TPCS 51.4M
  • KLRS 46.0M
  • IPO Year
  • TPCS N/A
  • KLRS N/A
  • Fundamental
  • Price
  • TPCS $5.59
  • KLRS $3.64
  • Analyst Decision
  • TPCS
  • KLRS Buy
  • Analyst Count
  • TPCS 0
  • KLRS 1
  • Target Price
  • TPCS N/A
  • KLRS N/A
  • AVG Volume (30 Days)
  • TPCS 97.6K
  • KLRS 81.2K
  • Earning Date
  • TPCS 08-21-2025
  • KLRS 08-13-2025
  • Dividend Yield
  • TPCS N/A
  • KLRS N/A
  • EPS Growth
  • TPCS N/A
  • KLRS N/A
  • EPS
  • TPCS N/A
  • KLRS N/A
  • Revenue
  • TPCS $33,424,000.00
  • KLRS N/A
  • Revenue This Year
  • TPCS N/A
  • KLRS N/A
  • Revenue Next Year
  • TPCS N/A
  • KLRS N/A
  • P/E Ratio
  • TPCS N/A
  • KLRS N/A
  • Revenue Growth
  • TPCS 3.78
  • KLRS N/A
  • 52 Week Low
  • TPCS $2.05
  • KLRS $2.14
  • 52 Week High
  • TPCS $6.25
  • KLRS $24.15
  • Technical
  • Relative Strength Index (RSI)
  • TPCS 61.93
  • KLRS 76.26
  • Support Level
  • TPCS $4.85
  • KLRS $2.37
  • Resistance Level
  • TPCS $5.80
  • KLRS $3.96
  • Average True Range (ATR)
  • TPCS 0.43
  • KLRS 0.25
  • MACD
  • TPCS -0.04
  • KLRS 0.13
  • Stochastic Oscillator
  • TPCS 62.24
  • KLRS 80.77

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About KLRS Kalaris Therapeutics Inc. Common Stock

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: